Kalaris Therapeutics Inc. Ordinary Shares KLRS 深 沪
等待开盘 10-23 09:30:00 美东时间
4.38
-0.350
-7.40%
华盛通- 最 高4.70
- 今 开4.70
- 成交量 9.70万股
- 最 低 4.27
- 昨 收 4.73
- 总市值 8191.65万
- 52周最高 24.15
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 2.14
- 委 比 53.58%
- 总股本 1870.24万
- 历史最高 1126.08
- 量 比 1.12
- 振 幅 9.09%
- 历史最低 4.27
- 每 手 1
- 风险率 4.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Kalaris Therapeutics has initiated a Phase 1b/2 multiple ascending dose (MAD) study for TH103 in patients with neovascular age-related macular degeneration (nAMD). The study, enrolling up to 80 patients, aims to evaluate the safety and preliminary efficacy of monthly intravitreal injections, with initial data expected in late 2026. TH103, a novel anti-VEGF therapy, is designed to provide increased and longer-lasting activity. The Phase 1a single ...
09-15 12:00
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Raymond James Initiates Coverage On Kalaris Therapeutics with Strong Buy Rating, Announces Price Target of $23
Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and announces Price Target of $23.
09-04 00:47
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc. (NYSE:SNOW) rose sharply in pre-market trading after t...
08-28 17:48
Kalaris Therapeutics Q2 EPS $(0.61) Misses $(0.52) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 85.68 percent increase over losses of $(4.26) per share
08-13 20:06
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics is enrolling treatment-naïve nAMD patients in a Phase 1 trial of TH103, a novel anti-VEGF agent designed for longer-lasting efficacy, with initial data expected in Q4 2025. The company reported $88.4M in cash as of June 2025, sufficient for operations into Q4 2026. Quarter-over-quarter increases in R&D and G&A expenses reflect ongoing clinical activities. Kalaris expanded its leadership with Kristine Curtiss as Senior Vice Pr...
08-13 12:00
Kalaris Therapeutics Adjusts Annual Meeting Schedule
Kalaris Therapeutics ( ($KLRS) ) has provided an announcement. Kalaris Therapeu...
06-20 19:48
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
Kalaris Therapeutics announces that its management will present at the Noble Capital Markets 2025 Virtual Equity Conference on June 5, 2025, at 3:00 PM ET. The presentation by CEO Andrew Oxtoby and CMO Matthew Feinsod will include a Q&A session. A replay will be available on Kalaris' Investor Relations webpage. The company focuses on developing treatments for retinal diseases, including TH103, an anti-VEGF therapy being tested for neovascular AMD...
06-02 12:00
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Quantum Computing Inc. (NASDAQ:QUBT) rose sharply in today's pre-mark...
05-16 16:56
